Study: Comparing biosimilar of ranibizumab and Lucentis in efficacy and safety for wet AMD

The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the two groups.

Spotlight on GA: A bright future with potential treatments

According to Rishi P. Singh, MD, family history and lifestyle are key in the development of geographic atrophy.

Aflibercept shown to work at higher dose, longer intervals

Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.

FDA approves ranibizumab-eqrn as a biosimilar product interchangeable with ranibizumab injection for all five indications

August 03, 2022

Retina indications for which ranibizumab-eqrn is interchangeable include neovascular (wet) age-related macular degeneration; macular edema following retinal vein occlusion; diabetic macular edema; diabetic retinopathy, and myopic choroidal neovascularization.

Two-year data confirms faricimab improves vision for patients diagnosed with wet-AMD

July 14, 2022

In the TENAYA and LUCERNE studies, more than 60% of faricimab patients could be treated every 4 months at 2 years, an increase from 45% at year 1. Study results are being presented at the American Society of Retina Specialists 2022 annual meeting in New York.